LIVZON PHARMAC. GRP H YC1 (LP6) — Working Capital to Net Assets Ratio
LIVZON PHARMAC. GRP H YC1 (LP6) has a Working Capital to Net Assets ratio of 49.2% as of March 2026. Working capital of €7.67 Billion (current assets of €15.66 Billion minus current liabilities of €7.99 Billion) is measured against net assets of €15.58 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See LP6 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
LIVZON PHARMAC. GRP H YC1 Working Capital to Net Assets (2021–2025)
This chart shows how LIVZON PHARMAC. GRP H YC1's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 49.2%, reflecting working capital of €7.67 Billion against net assets of €15.58 Billion EUR. For the complete balance sheet picture, see LP6 total asset value.
Annual Working Capital to Net Assets for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check LIVZON PHARMAC. GRP H YC1 (LP6) asset resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.2% | €8.90 Billion | €15.55 Billion | €16.12 Billion | €7.22 Billion | ▼ -1.8 pp |
| 2024 | 59.0% | €8.79 Billion | €14.91 Billion | €16.42 Billion | €7.63 Billion | ▼ -3.2 pp |
| 2023 | 62.2% | €9.18 Billion | €14.77 Billion | €17.27 Billion | €8.09 Billion | ▼ -2.0 pp |
| 2022 | 64.2% | €9.59 Billion | €14.94 Billion | €16.99 Billion | €7.40 Billion | ▲ +10.1 pp |
| 2021 | 54.1% | €7.75 Billion | €14.31 Billion | €14.67 Billion | €6.93 Billion | — |